Posted by Michael Wonder on 25 Jan 2025
X4 Pharmaceuticals announces EMA validation of marketing authorisation application for mavorixafor - licenced to Norgine for commercialisation in Europe
24 January 2025 - Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their marketing authorisation application for mavorixafor for the treatment of WHIM syndrome (warts, hypogammaglobulinaemia, infections and myelokathexis), a rare primary immunodeficiency, has been validated for review and is now under evaluation with the EMA's CHMP.
In April 2024, mavorixafor received US FDA approval as Xolremdi, an oral, once daily treatment for use in patients 12 years of age and older with WHIM syndrome.
